Adage Capital Partners Portfolio holdings
AUM
$59.3B
This Quarter Return
+27.25%
1 Year Return
+26.26%
3 Year Return
+130.73%
5 Year Return
+248.99%
10 Year Return
+658.76%
AUM
$39.1B
AUM Growth
+$39.1B
(+17%)
Cap. Flow
-$1.07B
Cap. Flow
% of AUM
-2.74%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
264
Reduced
307
Closed
110
Top Buys
| 1 |
Royalty Pharma
RPRX
|
$2.23B |
| 2 |
Otis Worldwide
OTIS
|
$211M |
| 3 |
Burlington
BURL
|
$200M |
| 4 |
AbbVie
ABBV
|
$199M |
| 5 |
Wayfair
W
|
$190M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$1.66B |
| 2 |
Lockheed Martin
LMT
|
$327M |
| 3 |
Johnson & Johnson
JNJ
|
$253M |
| 4 |
Pfizer
PFE
|
$153M |
| 5 |
Target
TGT
|
$148M |
Sector Composition
| 1 | Technology | 21.53% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.1% |
| 4 | Financials | 11.32% |
| 5 | Industrials | 8.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
626
Fox Class B
FOX
$24.8B
| $4.91M | 0.01% |
182,752
-4,468
| -2% | -$120K |
|
627
KalVista Pharmaceuticals
KALV
$719M
| $4.84M | 0.01% |
400,000
| – | – |
|
|
EIGR
628
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $4.8M | 0.01% |
500,000
+306,626
| +159% | +$2.94M |
|
629
Euronet Worldwide
EEFT
$3.74B
| $4.79M | 0.01% |
+50,000
| New | +$4.79M |
|
630
Stoke Therapeutics
STOK
$1.07B
| $4.77M | 0.01% |
200,000
| – | – |
|
631
DXC Technology
DXC
$2.57B
| $4.74M | 0.01% |
287,478
-35,242
| -11% | -$581K |
|
632
Arcturus Therapeutics
ARCT
$453M
| $4.67M | 0.01% |
+100,000
| New | +$4.67M |
|
633
Norwegian Cruise Line
NCLH
$11.2B
| $4.66M | 0.01% |
283,600
+35,600
| +14% | +$585K |
|
634
Invesco
IVZ
$9.66B
| $4.64M | 0.01% |
430,869
-7,100
| -2% | -$76.4K |
|
635
Cincinnati Financial
CINF
$23.9B
| $4.62M | 0.01% |
+72,100
| New | +$4.62M |
|
636
IDEX
IEX
$12.2B
| $4.47M | 0.01% |
28,276
-13,150
| -32% | -$2.08M |
|
637
Ascendis Pharma
ASND
$12.1B
| $4.44M | 0.01% |
30,000
-10,000
| -25% | -$1.48M |
|
638
Warner Music
WMG
$17.3B
| $4.43M | 0.01% |
+150,000
| New | +$4.43M |
|
639
Steris
STE
$23.8B
| $4.36M | 0.01% |
28,421
-27,064
| -49% | -$4.15M |
|
640
RenaissanceRe
RNR
$11.5B
| $4.28M | 0.01% |
+25,000
| New | +$4.28M |
|
641
Endava
DAVA
$853M
| $4.18M | 0.01% |
86,612
-13,388
| -13% | -$647K |
|
|
CFRX
642
DELISTED
ContraFect Corporation
CFRX
| $4.15M | 0.01% |
650,000
+362,000
| +126% | +$2.31M |
|
|
PARA
643
DELISTED
Paramount Global Class B
PARA
| $4.07M | 0.01% |
+174,408
| New | +$4.07M |
|
644
Aclaris Therapeutics
ACRS
$216M
| $4.05M | 0.01% |
2,500,000
+500,000
| +25% | +$810K |
|
645
PVH
PVH
$4.13B
| $4.01M | 0.01% |
83,500
-1,300
| -2% | -$62.5K |
|
646
Globe Life
GL
$11.3B
| $4M | 0.01% |
53,900
-30,800
| -36% | -$2.29M |
|
647
GeoPark
GPRK
$339M
| $3.92M | 0.01% |
400,000
+271,040
| +210% | +$2.65M |
|
648
Vroom, Inc. Common Stock
VRM
$146M
| $3.91M | 0.01% |
+75,000
| New | +$3.91M |
|
|
JNPR
649
DELISTED
Juniper Networks
JNPR
| $3.91M | 0.01% |
170,900
+11,300
| +7% | +$258K |
|
650
Artivion
AORT
$2.06B
| $3.83M | 0.01% |
200,000
-25,000
| -11% | -$479K |
|